Monte Rosa Therapeutics, Inc.
GLUE
$15.50
-$0.34-2.15%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.49% | 3.54% | -70.36% | -120.26% | -126.22% |
| Total Depreciation and Amortization | -1.87% | -3.22% | 1.06% | -0.33% | 4.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.79% | 16.06% | 14.17% | -7.91% | -2.61% |
| Change in Net Operating Assets | -5,508.51% | 104.19% | -102.77% | 523.30% | 70.90% |
| Cash from Operations | -18.05% | 13.12% | -142.83% | 389.25% | 23.68% |
| Capital Expenditure | -152.84% | -143.55% | -17.82% | 61.59% | -6.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 90.69% | -303.01% | -265.77% | 43.56% | 127.39% |
| Cash from Investing | 88.94% | -301.13% | -270.61% | 50.60% | 125.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.08% | 1,065.81% | 8,515.23% | -4.66% | 2,507.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -5,834.73% | -- | -- | -- |
| Cash from Financing | -99.02% | 1,008.34% | 8,412.64% | -4.66% | 2,507.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -332.78% | 138.20% | -156.48% | 1,638.19% | 93.80% |